Publikationer

Sortér efter: Dato | Forfatter | Titel

Moseholm, E., Omland, L. H., Katzenstein, T. L., Pedersen, G., Johansen, I. S., Storgaard, M. & Weis, N. (2025). Retention in care and viral suppression in pregnant/postpartum vs. nonpregnant/nonpostpartum women with HIV. AIDS, 39(13), 1936-1945. https://doi.org/10.1097/QAD.0000000000004275
Margolinsky, R. V., David Ruban, S., Agergaard, J., Wejse, C. M., Hvass, A. M. F., Stecher, C. W., Frederiksen, H. W. & Nørredam, M. L. (2025). Rethinking health equity for complex migrant patients: Insights from three specialized migrant health clinics in Denmark. European Journal of Public Health, 35(Suppl 6). Artikel doi: 10.1093/eurpub/ckaf180.032. https://doi.org/10.1093/eurpub/ckaf180.032
Kraef, C., Omland, L. H., Porskrog, A., Larsen, C. S., Dalager-Pedersen, M., Kronborg, G., Gerstoft, J., Kirk, O., Obel, N. & Johansen, I. S. (2025). Risk of Cancer After Tuberculosis Disease Among People With HIV in Denmark: A Nationwide Population-Based Cohort Study. Journal of Infectious Diseases, 232(3), 612-619. https://doi.org/10.1093/infdis/jiaf341
Pareek, M., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager-Pedersen, M., Claggett, B. L., Janstrup, K. H., Bartholdy, K. V., Bernholm, K. F., Borchsenius, J. I. M. H., Davidovski, F. S., Davodian, L. W., Dons, M., Duus, L. S. ... Biering-Sørensen, T. (2025). Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine: A Prespecified Secondary Analysis of the Randomized DANFLU-2 Trial. JAMA network open, 8(8), Artikel e2536889. https://doi.org/10.1001/jamanetworkopen.2025.36889
Virdee, A. K., Knudtzen, F. C., Llibre, J. M., Omland, L. H., Obel, N., Stærke, N. B., Åhsberg, J., Ørsted, I., Kronborg, G., Mohey, R., Montejo, M. D. P. F., Johansen, I. S. & Martin-Iguacel, R. (2025). Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy: A Danish Nationwide Prospective Cohort Study. Clinical Infectious Diseases, 80(4), 854-863. https://doi.org/10.1093/cid/ciae499
Højte, C., Olsen, M. F., Faurholt-Jepsen, D., Jørgensen, M. H., Pressler, T., Leo-Hansen, C., Bryrup, T., Jeppesen, M., Olesen, H. V., Petersen, J., Katzenstein, T. L., Nielsen, B. U., Skov, M. & the TransformCF study group (2025). Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort. Journal of Cystic Fibrosis, 24(5), 998-1005. https://doi.org/10.1016/j.jcf.2025.08.008